1912 - Citalopram

Citalopram and escitalopram represent medication of the ‘SSRI’ group of selective serotonin reuptake inhibitors, but escitalopram is the active s-enantiomer ingredient in citalopram. Both agents are administered for the treatment of depression, panic attacks, obsessive-compulsive disorders and ‘angst’ complaints, for their anti-depressive characteristics. The medical effect is based on the inhibition of the reuptake of serotonin in the presynaptic cells, whereby serotonin develops a longer time effect on the post-synaptic membranes and thus combats depression. Possible side effects range from somnolence, agitation through to libido diminution.

Type of drug: Antidepressant
Metabolism: CYP2C19, CYP2D6, CYP3A4, P-gp(ABCB1)
Half life t½: 38-48h
Steady State: 1 week
TDM: highly recommended/ norm of treatment
Additional informations: Metabolite may have a slight influence on pharmacology